T-allo-10

N/A

Report date: 2023/01/12 15:52:00

Base Information

Drug NameT-allo-10
Drug Alias NameT-allo-10
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionAnti-CD4
TargetsT-cell surface antigen CD4
Therapy Area/IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesHematologic Diseases +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesStanford University
China Registration ClassN/A

Develop Information

Active CompaniesCalifornia Institute For Regenerative MedicineStanford University
Inactive CompaniesNational Cancer Institute
Active IndicationsGraft vs Host DiseaseHematologic Diseases
Inactive IndicationsMyelodysplastic SyndromesLymphoma, Non-HodgkinHodgkin Disease +[6] 

Other Information

ATC CodeN/A
Related LinksN/A